Skip to main content
All lobbying filings

LUPIN PHARMACEUTICALS INC

Lobbying for LUPIN PHARMACEUTICALS INC

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · Maryland · House · Senate · $80,766.00 expenses · posted Jan 20, 2026

Official filing document

 Lobbying activity 4
Health Issues

Patent Thickets, Patent Settlements, Interchangeability of biosimilars, Q1Q2 transparency, PBM Reform, Inflation Reduction Act, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.

Medicare/Medicaid

Reimbursement of generic pharmaceuticals and biosimilars.

Pharmacy

Country of Origin labeling.

Manufacturing

Incentivizing domestic manufacturing of essential medicines.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem